Antibody Identification and Compatibility Testing

Antibody identification is the laboratory process of detecting and naming the red-cell antibodies in a patient's plasma, and compatibility (crossmatch) testing is the final check that a selected donor unit will not react with those antibodies. Together they constitute pretransfusion testing: an antibody screen flags the presence of unexpected antibodies, an identification panel determines their specificity, and the crossmatch confirms that the chosen unit is compatible before it is issued.

Definition

Antibody identification determines the specificity of unexpected red-cell antibodies in a patient's plasma by testing it against panels of reagent cells of known antigen makeup; compatibility testing confirms, by serologic or electronic crossmatch, that a chosen donor unit lacks the corresponding antigen and will not be destroyed by the recipient's antibodies.

Scope

This topic covers the antibody screen, the identification panel and its interpretation, the role of the indirect antiglobulin (indirect Coombs) test, and the immediate-spin, antiglobulin, and electronic crossmatch methods used to confirm compatibility. It also touches on the distinction between alloantibodies and autoantibodies. It is a reference and educational overview, not a bench protocol or clinical directive.

Core questions

• Does the patient's plasma contain unexpected red-cell antibodies?
• What is the specificity of any antibody detected?
• Is the selected donor unit compatible with the recipient's plasma?
• When is a serologic crossmatch required rather than an electronic one?

Key concepts

• Antibody screen
• Antibody identification panel
• Indirect antiglobulin (indirect Coombs) test
• Alloantibody versus autoantibody
• Antigen-negative unit selection
• Immediate-spin crossmatch
• Antiglobulin crossmatch
• Electronic (computer) crossmatch
• Antigen frequency and rule-out logic

Mechanisms

Pretransfusion testing exploits antigen-antibody binding. The patient's plasma is incubated with reagent red cells expressing known antigens; an antibody present binds its target, and the indirect antiglobulin test then bridges antibody-coated cells with anti-human globulin to produce visible agglutination. By comparing the pattern of reactive and non-reactive cells against the panel's antigen grid, the laboratory rules antibody specificities in or out. Once a specificity is known, antigen-negative donor units are selected, and a crossmatch — serologic when antibodies are present, or electronic when the screen is negative and records permit — confirms compatibility before issue. If incompatible blood were transfused, recipient antibody binding could trigger complement-mediated or extravascular haemolysis (Panch et al., 2019; Reid & Lomas-Francis, 2004).

Clinical relevance

Antibody identification and compatibility testing are the safeguards that prevent haemolytic transfusion reactions, and they grow more demanding in chronically transfused and alloimmunised patients who form multiple antibodies. As a reference topic this entry explains how these tests work and why they matter; it does not specify which units to release for a given patient or how to manage a reaction, which are clinical responsibilities (Panch et al., 2019; Hendrickson & Tormey, 2016).

Epidemiology

Unexpected red-cell antibodies are found in a minority of patients overall but are markedly more common in those repeatedly transfused, such as people with sickle cell disease or thalassaemia, where cumulative antigen exposure drives alloimmunisation. The probability of forming antibodies depends on antigen immunogenicity and host and inflammatory factors, which is why screening is repeated and antigen-matched strategies are used in high-risk groups (Hendrickson & Tormey, 2016).

History

The decisive advance was the antiglobulin test described by Coombs, Mourant, and Race in the 1940s, which made it possible to detect non-agglutinating IgG antibodies and so to identify the clinically important antibodies that simple saline techniques missed. Reagent red-cell panels with defined antigen profiles, standardised by reference laboratories, turned antibody identification into a systematic rule-out exercise, and the later acceptance of the electronic crossmatch streamlined compatibility confirmation when no antibodies are present (Reid & Lomas-Francis, 2004; Storry et al., 2013).

Key figures

• Robin Coombs
• Sandra Nance
• Jeanne Hendrickson
• Marion Reid

Seminal works

• panch-2019
• hendrickson-2016
• storry-2013

Frequently asked questions

What is the difference between an antibody screen and an antibody identification panel?

An antibody screen uses a small set of reagent cells to detect whether any unexpected antibody is present. If the screen is positive, an identification panel of many cells with different antigen profiles is tested to determine the antibody's specificity.

What is an electronic crossmatch?

An electronic or computer crossmatch confirms ABO compatibility through validated records and software rather than a physical serologic test. It is permitted only when the recipient has no detectable unexpected antibodies and the required typing and identity checks are in place.